Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: Is the fenfluramine challenge test still relevant?

Psychiatry Research

Volumn 87, Issue 2-3, 1999, Pages 107-115

  Steiner, Meir ^a   Yatham, Lakshmi N ^b   Coote, Margaret ^a   Wilkins, Annette ^a   Lepage, Patricia ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Fenfluramine challenge; Premenstrual dysphoria; Serotonin

Indexed keywords

FENFLURAMINE; IMIPRAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPHORIA; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; LUTEAL PHASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROLACTIN RELEASE; PROVOCATION TEST; RADIOIMMUNOASSAY; RECEPTOR BINDING; RECEPTOR DENSITY; SEROTONINERGIC SYSTEM;

EID: 0032698467     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00062-1     Document Type: Article

References (35)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;717-718 American Psychiatric Association, Washington, DC.
2. Ashby C.R. Jr., Carr L.A., Cook C.L., Steptoe M.M., Franks D.D. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biological Psychiatry. 24:1988;225-233.
3. Bancroft J., Cook A. The neuroendocrine response to D-fenfluramine in women with premenstrual depression. Journal of Affective Disorders. 36:1995;57-64.
4. Cleare A.J., Bond A.J. Does central serotonergic function correlate inversely with aggression? A study using D-fenfluramine in healthy subjects. Psychiatry Research. 69:1997;89-95.
5. Coccaro E.F., Kavoussi R.J., Cooper T.B., Hauger R.L. Hormonal responses to D- and D,L-fenfluramine in healthy human subjects. Neuropsychopharmacology. 15:1996;595-607.
6. Coccaro E.F., Kavoussi R.J., Cooper T.B., Hauger R. 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to D-fenfluramine challenge in healthy human subjects. Psychopharmacology. 127:1996;108-112.
7. Coccaro E.F., Kavoussi R.J., Oakes M., Cooper T.B., Hauger R. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to D-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 126:1996;24-30.
8. Dyck-Flory J.D., Mann J.J., Manuck S.B., Muldoon M.F. Recovery from major depression is not associated with normalization of serotonergic function. Biological Psychiatry. 43:1998;320-326.
9. Ellis P.M., Salmond C. Is platelet imipramine binding reduced in depression? A meta-analysis. Biological Psychiatry. 36:1994;292-299.
10. Eriksson E., Hedberg M.A., Andersch B., Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 12:1995;167-176.
11. FitzGerald M., Malone K.M., Li S., Harrison W.M., McBride P.A., Endicott J., Cooper T., Mann J.J. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. American Journal of Psychiatry. 154:1997;556-558.
12. Garattini S., Caccia S. Comparison of the plasma levels of fenfluramine in rats after a toxic dose and in man after a maximal therapeutic dose. Toxicology Letters. 3:1979;285-290.
13. Goodall E.M., Cowen P.J., Franklin M., Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to D-fenfluramine in human volunteers. Psychopharmacology. 112:1993;461-466.
14. Lee M.A., Nash J.F., Barnes M., Meltzer H.Y. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Psychopharmacology. 103:1991;258-264.
15. Lepage P., Steiner M. Gender and serotonergic dysregulation: implications for late luteal phase dysphoric disorder. Cassano G.B., Akiskal H.S. Serotonin-Related Psychiatric Syndromes: Clinical and Therapeutic Links, International Congress and Symposium Series Number 165. 1991;131-143 Royal Society of Medicine Services Limited, London, UK.
16. Lichtenberg P., Shapira B., Gillon D., Kindler S., Cooper T.B., Newman M.E., Lerer B. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Research. 43:1992;137-146.
17. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-271.
18. Malone K.M., Thase M.E., Mieczkowski T., Myers J.E., Stull S.D., Cooper T.B., Mann J.J. Fenfluramine challenge test as a predictor of outcome in major depression. Psychopharmacology Bulletin. 29:1993;155-161.
19. McBride P.A., Tierney H., DeMeo M., Chen J-S., Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biological Psychiatry. 27:1990;1143-1155.
20. Mitchell P., Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. Journal of Affective Disorders. 19:1990;43-51.
21. Muldoon M.F., Manuck S.B., Jansma C.L., Moore A.L., Perel J., Mann J.J. D,L-Fenfluramine challenge test: experience in nonpatient sample. Biological Psychiatry. 39:1996;761-768.
22. Newman M.E., Shapira B., Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. International Journal of Neuropsychopharmacology. 1:1998;49-69.
23. O'Keane V., O'Hanlon M., Webb M., Dinan T. D-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clinical Endocrinology. 34:1991;289-292.
24. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clinical Chemistry. 40:1994;288-295.
25. Park S.B., Cowen P.J. Effect of pindolol on the prolactin response to D-fenfluramine. Psychopharmacology. 118:1995;471-474.
26. Palazidou E., Stephenson J., Butler J., Coskeran P., Chambers S., McGregor A.M. Evidence for 5-hydroxytryptamine 1A receptor involvement in the control of prolactin secretion in man. Psychopharmacology. 119:1995;311-314.
27. Pearlstein T.B., Stone A.B., Lund S.A., Scheft H., Zlotnick C., Brown W.A. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology. 17:1997;261-266.
28. Quattrone A., Tedeschi G., Aguglia U., Scopacasa F., Di Renzo G.F., Annunziato L. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. British Journal of Clinical Pharmacology. 16:1983;471-475.
29. Rojansky N., Halbreich U., Zander K., Barkai A., Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecologic and Obstetric Investigation. 31:1991;146-152.
30. Spitzer R.L., Endicott J., Robins E. Research Diagnostic Criteria: rationale and reliability. Archives of General Psychiatry. 35:1978;773-782.
31. Steege J.F., Stout A.L., Knight D.L., Nemeroff C.B. Reduced platelet tritium-labelled imipramine binding sites in women with premenstrual syndrome. American Journal of Obstetrics and Gynecology. 167:1992;168-172.
32. Steiner M. Premenstrual syndromes. Annual Review of Medicine. 48:1997;447-455.
33. Steiner M., Judge R., Kumar R. Serotonin re-uptake inhibitors in the treatment of premenstrual dysphoria: current state of knowledge. International Journal of Psychiatry in Clinical Practice. 1:1997;241-247.
34. Veeninga A.T., Westenberg H.G.M. Serotonergic function and late luteal phase dysphoric disorder. Psychopharmacology. 108:1992;153-158.
35. Yatham L.N., Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sciences. 53:1993;447-463.